Back to search

Article

Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in Greece

2021-06-11

Abstract excerpt

Real world data regarding the effectiveness and safety of the new COVID-19 vaccines in older people are currently lacking. The over-85 age group was the first group to receive the BNT162b2 mRNA COVID-19 vaccine in Greece according to the national priority vaccination scheme. The aim of the study was to enhance insight into the antibody generation elicited by the BNT162b2 mRNA COVID-19 vaccine among elderly people...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7ee65748-1ebd-52bb-ada6-8d3f5186a0e0
DOI
10.2139/ssrn.3850394
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceDOI 10.2139/ssrn.3850394
Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare WorkersSemantic proximity
Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Immunocompromised Adults in Greece: Necessity of a Fourth DoseSemantic proximity
Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workersSemantic proximity
BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantSemantic proximity
STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity
GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccineSemantic proximity
Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationSemantic proximity
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity
Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity
Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccinationSemantic proximity
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S VaccinesSemantic proximity
Select a neighboring publication to make it the new centre.